3rd Annual Personalized Cancer Vaccine Summit 2026 | December 1-3, 2026
The personalized cancer vaccine field has reached a defining milestone. With Moderna and Merck reporting positive initial Phase 3 data for intismeran autogene in combination with Keytruda, the first regulatory approval of a personalized neoantigen cancer vaccine is now firmly within sight, accelerating momentum across the entire industry.
Yet significant challenges remain. As innovation accelerates, organizations must overcome key challenges spanning development, manufacturing, delivery, and market access.
The 3rd Annual Personalized Cancer Vaccine Summit brings together leaders from across Moderna, Medici Therapeutics, Geneos Therapeutics, Nykode Therapeutics, Echo Immune, HDT Bio, Mayo Clinic, Transgene, and more, to share data-driven insights, benchmark strategies and forge long-term partnerships for driving personalized cancer vaccines closer to approval.
Explore the full 3-day experience here: https://ter.li/1hlwywn3
Join 80+ personalized cancer vaccine leaders to:
- Explore emerging clinical data shaping the future of individualized cancer immunotherapies
- Optimize neoantigen selection strategies to improve immunogenicity, response rates, and clinical outcomes
- Accelerate development timelines through advances in manufacturing, automation, and vein-to-vaccine workflows
- Establish commercially viable processes by addressing sustainable cost of goods and scalable production models
- Navigate evolving regulatory and clinical development pathways to support successful approval
View and download the agenda here to explore the opportunity: https://ter.li/1hlwywn3
